Global Triamterene Tablets Market Overview:
Triamterene is a prescription medication used to treat edoema caused by congestive heart failure, liver cirrhosis, and the nephrotic syndrome, as well as steroid-induced edoema, idiopathic edoema, and secondary hyperaldosteronism. Triamterene is a potassium-sparing (antikaliuretic) diuretic of limited natriuretic activity. It acts as a diuretic by inhibiting sodium reabsorption in exchange for potassium and hydrogen in the distal renal tubule. Triamterene decreases the unnecessary loss of potassium and hydrogen associated with hydrochlorothiazide by increasing sodium excretion. The ingestion of triamterene or hydrochlorothiazide from triamterene and hydrochlorothiazide tablets is unaffected by food. Triamterene and hydrochlorothiazide pills, USP are used to treat hypertension and edoema in patients who have acquired hypokalemia. This prescription can be used individually or in combination with other antihypertensive medications. Some of the players profiled in the study are GlaxoSmithKline plc (United Kingdom), Apotex Inc. (Canada), Actavis Inc. (Teva Pharma) (United States), Zydus Pharmaceuticals Inc. (United States), BluePoint Laboratories (United States), Mylan N.V. (United States), Advanz Pharma (United Kingdom), Watson Pharma (Teva Pharma) (United States), Lupin Limited (India) and Zydus Cadila (India).
On the basis of geography, the market of Triamterene Tablets has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Metabolic or Respiratory Acidosis will boost the Triamterene Tablets market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Packaging, the sub-segment i.e. Blister will boost the Triamterene Tablets market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Adults will boost the Triamterene Tablets market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Growth Drivers
- Rising Healthcare Awareness
- Growth in Healthcare and Pharma Infrastructure
- Increasing R&D on in Healthcare industry
- Side Effects and Adverse Reactions Including Depression and Hypersensitivity
- Low Penetration in Emerging Economies Particularly in Asian Region
- Regulatory Approvals
- Fierce Competitive Pressures
Key Market Developments:
On 13th February, 2019 - Zydus Cadila (India Based Pharma Manufacturer) Received FDA Clearance for Its Triamterene & Hydrochlorothiazide Capsules, Applicable to Treat High Blood Pressure and Hypertension.
United States, Food and Drug Administration “Hydrochlorothiazide; Triamterene” - USDA is the key Regulatory Authority Responsible for Approval, Inspection and Dosage Limitations of Triamterene Tablets across the United States, FDA limits the usage to licensed prescription holders only. Any New Entrant is Required to have a Regulatory Clearance form FDA.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Target Audience:Triamterene Tablets Manufactures, New Entrants and Investors, Triamterene Tablets Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Major Objectives Focused through this Study To define, describe, and forecast the Global Triamterene Tablets market on the basis of product  , application [Hospital, Retail Pharmacies and Other], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Triamterene Tablets market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Triamterene Tablets industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Prasco Laboratories (United States), Enomark Biotech (India), WellSpring Pharmaceutical (United States), DHP Healthcare (United Kingdom), AvKARE Inc. (Amneal Pharma) (United States), Eskayef Pharmaceuticals Ltd. (Bangladesh) and Viona Pharmaceuticals (United States).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Triamterene Tablets market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.